Recurrent HR+ Breast Cancer
Recurrent HR+ Breast Cancer
A 58-Year-Old Woman With Recurrent HR+ Breast Cancer
December 2013
- A 58-year-old postmenopausal woman was referred for further evaluation of a suspicious left-sided lesion found incidentally on routine mammogram
- MRI revealed a 4.3-cm lesion in her left breast
- PMH unremarkable
- She underwent lumpectomy with axillary staging
- Biopsy findings:
- Histology: lobular carcinoma, grade 2
- Hormone receptor status: ER+/ PR (-)
- HER2,IHC 1+
- OncotypeDx RS, 19
- Staging, T2N0M0
- ECOG 0
- She was started on adjuvant anastrozole
September 2018
- On routine follow-up, the patient reports increasing fatigue and intermittent bouts of abdominal pain with nausea
- CT with contrast showed several small lesions in the liver; biopsy confirmed metastatic disease.
- The patient was started on ribociclib; anastrozole was changed to fulvestrant
- Imaging at 3 and 6 months showed a partial response
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More
